Cancer Progress Requires Integrating Data And Therapeutics – AACR Report
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
As genomic analysis produces ever-increasing amounts of data on cancer biology, continued progress in oncology will require advances in managing and analyzing data and new approaches to clinical trial design to increase efficiency and address development of treatment resistance to molecularly targeted therapies, the American Association for Cancer Research asserts in its annual Cancer Progress report.